Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists’ mindsets and investment theses will increase the probability of securing needed capital.
Published in Trends In Biotechnology
Authors: Nicholas Frame, PhD, Michael Casasanta, PhD, and Oded Ben-Joseph, PhD, MBA
Abstract:
Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists’ mindsets and investment theses will increase the probability of securing needed capital.
Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]
Read More
Outcome Capital Life Science Market Pulse May 2026 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?